Drug Patent Watch

DECEMBER 9, 2024

High-Throughput Screening: Modern Technology Meets Natural Products Advanced technologies now allow researchers to rapidly test thousands of natural compounds against specific disease targets. Artemisinin: Nobel Prize-Winning Malaria Treatment Artemisinin, derived from the sweet wormwood plant, has become a crucial treatment for malaria.

Drugs 96

Drugs Drug Development Pharmaceuticals Production 96

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. But a new path for bringing treatments to patients is starting to emerge. The following conversation was edited for length and clarity.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

Drug Target Review

JANUARY 8, 2024

It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. Through years of scientific exploration and research, we now know there are several biological changes that make our bodies more susceptible to disease or injury, and we can target those with therapeutic interventions.

Science 145

Science Disease FDA Approval Clinical Trials 145

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). The pipeline currently includes five drug candidates, all of which have the potential to revolutionise the treatment of PD.

Disease 52

Disease Drugs Treatment Drug Development 52

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

DrugBank

SEPTEMBER 19, 2024

Oral drug delivery remains the gold standard in pharmaceutical administration. It offers convenience for patients, promotes medication adherence, and improves treatment outcomes. This could aid in treatment for diabetic patients who currently rely on injections. This approach holds promise for delivering drugs to tumor sites.

Pharmacokinetics 98

Pharmacokinetics Drugs Treatment Disease 98

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

SEPTEMBER 3, 2020

Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

Drug Target Review

DECEMBER 11, 2024

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

International 52

International Laboratories Drugs Pharmacokinetics 52

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? What is the ultimate impact of heterogeneity associated with these disorders and diseases? The lack of heterogeneity can introduce significant risk into mid- to late-stage studies.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

DrugBank

JUNE 27, 2024

Opportunities in Drug Repurposing There is great potential for drug repurposing to unlock treatments for rare and neglected diseases, where traditional drug development is too costly. Pharma companies are often rich with valuable chemical libraries and expertise, while academics bring emerging disease biology knowledge.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

KIF1A

JULY 1, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But promising drugs that didn’t make the cut for treating one disorder may still be effective for other rare diseases. What’s a pre-print?

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

The Pharma Data

JANUARY 5, 2021

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course.”. Disease Highlights. ” Dr.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

MARCH 7, 2022

Astellas”) today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions.

Treatment 52

Treatment Clinical Trials Trials Pharmaceutical Companies 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

MARCH 13, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanadelumab subcutaneous injection, a monoclonal antibody therapy for prophylaxis against attacks of hereditary angioedema (HAE).

Treatment 52

Treatment Pharmacokinetics Drugs Production 52

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). 1 The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta (A?) in individuals newly treated with lecanemab and was presented at the 2021 Alzheimer’s Disease and Parkinson’s Disease Conference.

Disease 40

Disease Treatment Therapies FDA 40

DrugBank

DECEMBER 18, 2024

These interventions target a broad spectrum of medical conditions, encompassing chronic diseases and even substance abuse. DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Many cancer treatments target DNA, but often these can cause collateral damage, leading to severe side effects.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

DrugBank

JANUARY 15, 2025

Introduction Orphan drugs, specifically developed to treat rare diseases, represent a unique and challenging pharmaceutical industry segment. However, their significance in addressing the unmet medical needs of patients with rare diseases must be considered. Estimates show the median price of developing an orphan drug to be $2.6

Drugs 52

Drugs Drug Development Clinical Trials Therapies 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of digital health and data, there are endless possibilities for reaching vulnerable populations and improving access to treatment.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

Crown Bioscience

MAY 4, 2021

Why are cancer treatments for children lagging behind the latest advancements in clinical oncology? Pediatric cancer has been a low priority for pharmaceutical companies due to a combination of factors, including scientific hurdles, additional regulatory burdens, and financial disincentives.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

APRIL 19, 2024

The scientific founders have developed a pioneering method for drug discovery that applies to the research and design of new drugs effective against diseases that are incurable to date. We also have collaborations with pharmaceutical companies where we leverage the best of our unique platform and pharma expertise on the target.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

The Pharma Data

NOVEMBER 9, 2020

An experimental Alzheimer’s disease treatment should not be approved by the U.S. The drug, developed by the pharmaceutical company Biogen and its Japanese partner Eisai, is administered through intravenous infusion for early Alzheimer’s disease.

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment FDA Disease 52

Broad Institute

AUGUST 20, 2024

By Allessandra DiCorato August 20, 2024 Credit: Elizabeth Gribkoff, Eric and Wendy Schmidt Center Yue Qin, a postdoctoral fellow in the Eric and Wendy Schmidt Center, wants to create an in silico cell — a computational model scientists can use to study at scale how external influences such as drug treatments affect cells.

Science 69

Science Bioinformatics Disease Treatment 69

Altus Drug Development

JUNE 30, 2022

While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. This novel approach promises to create great advantages for the pharmaceutical companies who adopt it and might become the future of medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

The Premier Consulting Blog

MAY 17, 2023

It is an unfortunate reality that many diseases and conditions affect such small numbers of patients that, when a sponsor develops a drug or biological product to treat them, relatively little return on investment is generated to offset the high development costs.

Drugs 52

Drugs Disease Production Clinical Trials 52

Drug Target Review

MAY 23, 2023

Inflammatory bowel disease (IBD) is an umbrella term that describes complex disorders that cause chronic inflammation in the digestive tract with alternating periods of relapse and remission. Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. More than 6.8

Drugs 75

Drugs Small Molecule Production Disease 75

H1 Blog

DECEMBER 11, 2024

As pharmaceutical companies shift their focus toward fewer, high-value therapeutic areas in light of the IRAs drug price negotiations, the overall number of clinical trials will go down. This makes it more difficult for patients to afford treatments and contributes to health inequity.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Treatment 52

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. Could you give us an overview of the Lineage platform?

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84